Attovia Therapeutics, Inc. (ATTO) Stock Price & Analysis
Attovia Therapeutics, Inc. (ATTO) closed at USD 14.78 on Thursday, October 15, 2026, down 1.20% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 14.96; the Oct 15, 2026 session ranged USD 14.61–15.5 on volume of 641,397 shares. Market capitalization is $674.73M, with a 52-week range of USD 14.23–28 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:19 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ATTO.md
Key facts (ATTO)
- Analysts: Buy (mean 1.60 on a 1–5 scale) (5 analysts), mean target USD 42.2 (range 30–52).
- Total return with dividends: 1Y -32.5% vs S&P 500 +18.1%; 5Y -26.7% vs S&P 500 +85.1%.
- Next earnings: 2026-11-11, EPS estimate USD -0.5, revenue estimate $0K.
Analysts (ATTO)
Consensus Buy (mean 1.60 on a 1–5 scale), 5 analysts; mean target USD 42.2 (low 30, high 52).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-31 | Citigroup | Initiated | Buy | $30 |
| 2026-08-31 | LifeSci Capital | Initiated | Outperform | $45 |
| 2026-08-31 | Leerink Partners | Initiated | Outperform | $52 |
| 2026-08-31 | RBC Capital | Initiated | Outperform | $45 |
| 2026-08-31 | Morgan Stanley | Initiated | Overweight | $39 |
Total return (dividends reinvested) (ATTO)
| 1Y (from 2026-08-05) | 5Y (from 2026-08-03) | |
|---|---|---|
| Total return | -32.5% | -26.7% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | — | — |
| Volatility (annualized) | 80.9% | 76.7% |
| Max drawdown | -42.9% (Sep 2026→Oct 2026) | -42.1% (Aug 2026→Oct 2026) |
Key Statistics (as of October 16, 2026 at 05:19 UTC)
| Price | USD 14.78 |
|---|---|
| Change | ▼ 1.20% (down) |
| Previous Close | USD 14.96 |
| Open | USD 14.74 |
| Day Range | USD 14.61 – 15.5 |
| 52-Week Range | USD 14.23 – 28 |
| Volume | 641,397 shares |
| Market Cap | $674.73M |
| Exchange | NGM |
Technical Analysis (ATTO)
Nexqual's technical model rates ATTO "SELL" based on 1 bullish and 5 bearish signals across 51 daily candles, as of October 16, 2026 at 05:19 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 33.4 (neutral) |
| vs SMA50 | Below (USD 19.97) |
| MACD | -1.57 (negative) |
Analyst Ratings (ATTO)
Wall Street analysts rate ATTO "Buy" based on 5 analysts, with a mean price target of USD 42.2 (range USD 30–52), per Nexqual as of October 16, 2026 at 05:19 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 42.2 |
| High Target | USD 52 |
| Low Target | USD 30 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (ATTO)
| Next Earnings Date | 2026-11-11 |
|---|---|
| EPS Estimate | USD -0.5 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -4.88 vs est -4.71 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financials & Fundamentals (ATTO)
| Total Revenue | $1.80M |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | -4845.11% |
| Profit Margin | +0.00% |
| Debt / Equity | 0.04 |
| Current Ratio | 9.39 |
| Total Cash | $115.13M |
| Total Debt | $4.33M |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financial Health Score (ATTO)
Nexqual rates Attovia Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:19 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $115M cash vs $4M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$67M (TTM) |
| Efficiency | Mixed — No data |
Ownership (ATTO)
| Insider Ownership | +9.05% |
|---|---|
| Institutional Ownership | +36.45% |
| Shares Outstanding | 45.65M |
| Float | 26.26M |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Leadership (ATTO)
Attovia Therapeutics, Inc. is led by Tao Fu M.B.A., M.S. (age 53), CEO, President & Director, per Nexqual as of October 16, 2026 at 05:19 UTC.
| CEO, President & Director | Tao Fu M.B.A., M.S. (age 53) |
|---|---|
| Chief Scientific Officer | Petter Veiby (age 60) |
| Chief Financial Officer | Steven Chan (age 53) |
| Chief Technology Officer | Hangjun Zhan (age 65) |
Major Backers & Investors (ATTO)
Notable institutional backers of Attovia Therapeutics, Inc. include Fidelity, according to Nexqual as of October 16, 2026 at 05:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 1.7% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:19 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt